Table 3.

Associations between regular use of aspirin and risk of pancreatic cancer, according to stage of disease and gendera

Aspirin useNo. of case patientsbNo. of control subjectsbOR (95% CI)P
n = 761n = 794
Local stage case patients vs. controls:
 Ever use
  No90651Ref.
  Yes131430.61 (0.33–1.15)0.13
 Duration of use, y2.044.060.81 (0.67–0.98)0.031
Regional stage case patients vs. controls:
 Ever use
  No386651Ref.
  Yes521430.56 (0.39–0.80)0.0013
 Duration of use, y3.654.060.92 (0.86–0.99)0.019
Distant stage case patients vs. controls:
 Ever use
  No198651Ref.
  Yes221430.46 (0.28–0.75)0.0020
 Duration of use, y4.364.060.93 (0.85–1.02)0.11
Male subjects:
 Ever use
  No378377Ref.
  Yes57830.64 (0.44–0.94)0.023
 Duration of use, y3.684.230.93 (0.87–1.00)0.045
Female subjects:
 Ever use
  No296274Ref.
  Yes30600.42 (0.26–0.67)10−3.5
 Duration of use, y3.413.820.89 (0.80–0.99)0.028
  • aUnconditional logistic regression models were used to obtain the ORs and 95% CIs. All models were adjusted for age at interview (continuous), sex, education category (continuous), BMII at age 21 (continuous), years of cigarette smoking (continuous), number of cigarettes per day (continuous), H. pylori CagA seropositivity, ABO blood group A vs. non-A, and history of diabetes mellitus more than 3 years in the past. Each row in the table is a separate adjusted model.

  • bNumbers of subjects for the category variables. For the duration variables, these columns give the mean durations among aspirin ever users; the ORs are per one year of duration, and the P values represent trend associations.